FindTrial
Sign In

RP-3500

DRUG5 trials

Sponsors

Debiopharm International SA, University of Utah, Memorial Sloan Kettering Cancer Center, Canadian Cancer Trials Group

Conditions

Advanced CancerAdvanced Solid TumorBreast CancerChronic Lymphocytic LeukemiaMetastatic CancerSolid Tumor

Phase 1

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
RecruitingNCT04855656
Debiopharm International SAAdvanced Solid Tumor
Start: 2021-04-30End: 2028-06-01Target: 464Updated: 2026-03-30
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
TerminatedNCT05405309
University of UtahChronic Lymphocytic Leukemia
Start: 2022-09-23End: 2025-01-10Updated: 2025-06-03
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Active, not recruitingNCT05566574
Memorial Sloan Kettering Cancer CenterMetastatic Cancer, Solid Tumor
Start: 2022-09-30End: 2026-09-30Updated: 2025-12-17

Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
RecruitingNCT05601440
Canadian Cancer Trials GroupBreast Cancer
Start: 2023-06-13End: 2028-06-30Target: 484Updated: 2026-03-27
RP-6306 in Patients With Advanced Cancer
CompletedNCT05605509
Canadian Cancer Trials GroupAdvanced Cancer
Start: 2023-05-24End: 2026-02-05Updated: 2026-02-06

Related Papers

IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.
Journal of Clinical Oncology2025-05-281 citations
Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)
Cancer Research2025-04-253 citations
Abstract IA010: Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic
Molecular Cancer Therapeutics2024-06-10
Abstract A017: Characterizing intratumoral heterogeneity of <i>CCNE1</i> amplification in ovarian cancer using digital pathology
Molecular Cancer Therapeutics2024-06-10
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
Journal of Medicinal Chemistry2024-02-0121 citations
Abstract A002: Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy
Cancer Research2024-01-09
Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with <i>CCNE1</i> amplification or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>
Molecular Cancer Therapeutics2023-12-0117 citations
Abstract A023: Preclinical development of PKMYT1 and WEE1 inhibitor combinations
Molecular Cancer Therapeutics2023-12-013 citations
Abstract B057: Preclinical development of PKMYT1 and ATR inhibitor combinations
Molecular Cancer Therapeutics2023-12-012 citations
Abstract B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring <i>CCNE1</i> amplification and/or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>
Molecular Cancer Therapeutics2023-12-01
<i>Coronado CLL</i>: A Phase Ib/II Trial of <i>Co</i>mbination <i>R</i>p-3500 and <i>O</i>laparib in DNA Damage Repair Pathway <i>D</i>eficient Relapsed/Refract <i>o</i>ry <i>C</i>hronic <i>L</i>ymphocytic <i>L</i>eukemia
Blood2023-11-021 citations
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
2023-06-0567 citations
Abstract 2132: Tumor heterogeneity of <i>CCNE1</i> copy number assessed by fluorescence <i>in situ</i> hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression
Cancer Research2023-04-04
Abstract 5650: RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in <i>CCNE1</i> amplified cancer cells
Cancer Research2022-06-151 citations